Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Drawing on the film Wonder, this article examines how a narrative of community acceptance offers sustaining relationships for people with unusual facial appearance.
AMA J Ethics. 2019;21(11):E1003-1008. doi:
10.1001/amajethics.2019.1003.
Withholding information from patients during an informed consent process is ethically unacceptable. Patients may restrict the amount of information they wish to receive or designate someone else to receive the information for them.
AMA J Ethics. 2015;17(3):209-214. doi:
10.1001/journalofethics.2015.17.3.ecas2-1503.
Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported.
AMA J Ethics. 2019;21(11):E968-973. doi:
10.1001/amajethics.2019.968.